Piramal Pharma and Ajinomoto Join ADC Collaboration

Piramal Pharma Solutions and Ajinomoto Bio‑Pharma Services announced a strategic collaboration to jointly support antibody‑drug conjugate (ADC) development and manufacturing.
Under the agreement, Piramal will refer customers to Ajinomoto’s AJICAP™ technology, and Ajinomoto will refer customers to Piramal for CDMO services.
The partnership includes an MTA allowing Piramal to manufacture AJICAP™‑based products, leveraging its role as the first FDA‑approved ADC CDMO.
Executives Peter DeYoung (Piramal) and Yasuyuki Otake (Ajinomoto) highlighted that the collaboration will accelerate innovation and expand global access to ADC therapies.